Lessons from the withdrawal of rofecoxib

Patients would be safer if drug companies disclosed adverse events before licensing

Saved in:
Bibliographic Details
Published in:BMJ 2004-10, Vol.329 (7471), p.867-868
Main Authors: Dieppe, Paul A, Ebrahim, Shah, Martin, Richard M, Jüni, Peter
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Arthritis
Clinical trials
Cyclooxygenase Inhibitors - adverse effects
Drug Approval
Heart attacks
Humans
Lactones - adverse effects
Pharmaceuticals
Side effects
Sulfones
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients would be safer if drug companies disclosed adverse events before licensing
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.329.7471.867